Analyst Ratings for Alnylam Pharmaceuticals
Portfolio Pulse from Benzinga Insights
In the last quarter, Alnylam Pharmaceuticals (NASDAQ:ALNY) received 3 bullish, 2 somewhat bullish, and 3 indifferent analyst ratings. The company's average 12-month price target is $256.25, up 26.54% from the previous average of $202.50.
June 22, 2023 | 4:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alnylam Pharmaceuticals received positive analyst ratings in the last quarter, with an average 12-month price target of $256.25, up 26.54% from the previous average.
The positive analyst ratings and increased average 12-month price target for Alnylam Pharmaceuticals indicate a bullish sentiment among analysts, which could lead to a short-term increase in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100